Trevi Therapeutics (TRVI) Tops Q2 EPS by 1c

Trevi Therapeutics (NASDAQ: TRVI) reported Q2 EPS of ($0.09), $0.01 better than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance
• Klarna shares tumble on weak full-year revenue guidance